SAVA - NASDAQ
Cassava Sciences, Inc.
$1.96
-6.5%Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
At a Glance
Live SnapshotCassava Sciences, Inc. Fair Value Envelope
Owner Earnings Valuation Tool
Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation
Historical Financial Data
Base year metrics used for projections
Projection Settings
Forecast period and terminal assumptions
DCF Valuation Summary
Calculation flow from present value to intrinsic value per share
Owner Earnings Projections
Operating Cash Flow - Maintenance CapEx = Owner Earnings
| Metric | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | Year 6 | Year 7 | Year 8 | Year 9 | Year 10 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$55.5M | -$95.4M | -$164.0M | -$281.9M | -$484.7M | -$833.5M | -$1.4B | -$2.5B | -$4.2B | -$7.3B |
| Maintenance CapEx | -$199.8K | -$343.5K | -$590.7K | -$1.0M | -$1.7M | -$3.0M | -$5.2M | -$8.9M | -$15.3M | -$26.2M |
| Owner Earnings | -$55.7M | -$95.7M | -$164.5M | -$282.9M | -$486.5M | -$836.5M | -$1.4B | -$2.5B | -$4.3B | -$7.3B |
| Discount Factor | 0.926 | 0.857 | 0.794 | 0.735 | 0.681 | 0.630 | 0.583 | 0.540 | 0.500 | 0.463 |
| Present Value | -$51.5M | -$82.0M | -$130.6M | -$208.0M | -$331.1M | -$527.1M | -$839.2M | -$1.3B | -$2.1B | -$3.4B |
Related Guides
Continue your SAVA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.